New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
09:28 EDTCNC, GILDCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Sterne Agee believes that Centene (CNC) is the best positioned among the health insurance companies focusing on Medicaid to beat the consensus Q2 EPS outlook. The firm thinks that increased revenue from Centene's specialty pharmacy unit may have more than offset its increased costs from Gilead's (GILD) Sovaldi in Q2. The firm keeps a Buy rating on Centene.
News For CNC;GILD From The Last 14 Days
Check below for free stories on CNC;GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
16:13 EDTGILDGilead raises FY14 net product sales guidance to $21B-$23B from $11.3B-$11.5B
Subscribe for More Information
16:09 EDTGILDGilead reports Q2 product revenue $6.41B vs. $2.66B last year
Reports Q2 Royalty, contract, and other revenues $122M vs. 110.1M last year. John C. Martin, PhD, Gileadís chairman and CEO stated, ďDuring Q2, Gilead continued to make significant progress led by strong Sovaldi sales. Since Decemberís launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical communityís recognition of the benefits of this product. We look forward to making Sovaldi available in additional countries.Ē
16:05 EDTGILDGilead reports Q2 EPS $2.36, consensus $1.79
Subscribe for More Information
16:01 EDTGILDGilead trading halted, pending news
Subscribe for More Information
16:00 EDTGILDOptions Update; July 23, 2014
iPath S&P 500 VIX Short-Term Futures up 23c to 28.17. Option volume leaders: AAPL FB C GILD MSFT PBR NFLX AMZN TWTR TSLA according to Track Data
15:43 EDTGILDGilead July weekly 90 straddle priced for 5.5% move into Q2
Subscribe for More Information
15:30 EDTGILDNotable companies reporting after market close
Subscribe for More Information
11:40 EDTGILDFDA approves Zydelig for three types of blood cancers
Subscribe for More Information
July 22, 2014
13:46 EDTCNCCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTCNCAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRSís regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
06:47 EDTCNCCentene up 2.1% following Q2 earnings release
Subscribe for More Information
06:14 EDTCNCCentene sees FY14 EPS $3.70-$3.90, consensus $3.73
Subscribe for More Information
06:14 EDTGILDGilead July weekly volatility elevated into Q2
Subscribe for More Information
06:12 EDTCNCCentene reports Q2 EPS ex-items 95c, consensus 72c
Reports Q2 revenue $4.02B, consensus $3.66B. Reports Q2 EPS 79c. Reports Q2 premium and service revenues $3.74B.
July 21, 2014
16:00 EDTGILDOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
09:38 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTGILDGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
12:46 EDTGILDGilead drug cocktail helps treat HIV/HCV-coinfected patients, JAMA says
Subscribe for More Information
July 16, 2014
11:57 EDTGILDStocks with call strike movement; GILD YHOO
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use